Clinical trials
Dermatomyositis trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
28 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2016 | 1 |
| 2017 | 1 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 6 |
| 2023 | 4 |
| 2024 | 5 |
| 2025 | 5 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 13 |
| Unknown status | 9 |
| Enrolling by invitation | 3 |
| Completed | 2 |
| Active, not recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Chongqing Precision Biotech Co., Ltd | 4 |
| The First Affiliated Hospital with Nanjing Medical University | 4 |
| Peking Union Medical College Hospital | 3 |
| AstraZeneca | 2 |
| Pfizer | 2 |
| RenJi Hospital | 2 |
| argenx | 2 |
| First Affiliated Hospital Xi'an Jiaotong University | 1 |
| Jiangxi Provincial People's Hopital | 1 |
| Peking University People's Hospital | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Dermatomyositis | 28 |
| Polymyositis | 7 |
| Myositis | 5 |
| Lupus Erythematosus, Systemic | 4 |
| Arthritis, Juvenile | 3 |
| Scleroderma, Systemic | 3 |
| Arthritis, Rheumatoid | 2 |
| Autoimmune Diseases | 2 |
| Lung Diseases, Interstitial | 2 |
| Sjogren's Syndrome | 2 |
Trials
Showing 51 to 28 of 28. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.